Quantcast

Latest pulmonary fibrosis Stories

2014-07-02 08:27:39

RIDGEFIELD, Conn., July 2, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the New Drug Application (NDA) for its investigational compound nintedanib has been accepted for filing by the U.S. Food & Drug Administration (FDA) and granted Priority Review designation. The application for nintedanib is currently under review for the treatment of people with idiopathic pulmonary fibrosis (IPF), a rare, progressive and fatal lung disease that affects...

2014-06-24 12:28:44

RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S. multi-center expanded access program (EAP) for its investigational compound nintedanib, for people diagnosed with idiopathic pulmonary fibrosis (IPF) and who meet certain eligibility criteria. Nintedanib is an investigational therapy and has not been approved by the U.S. Food and Drug Administration (FDA). The safety and efficacy of...

2014-06-10 12:30:16

CHICAGO, June 10, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced a key partnership with Biogen Idec in support of the PFF Patient Registry. The PFF announced its plan to establish a PFF Patient Registry, along with a PFF Care Center Network (CCN), at its biennial PFF Summit held in December 2013. "Our partnership with Biogen Idec will further enhance the PFF Patient Registry, allowing us to investigate fundamentally important questions in...

2014-05-28 09:00:04

Helmholtz Zentrum München Scientists at the Helmholtz Zentrum München (HMGU) working in cooperation with the Ludwig-Maximilians-Universität Hospital and the Technische Universität München (TUM) have for the first time tested X-ray dark-field radiography on a living organism to diagnose lung disease. This enables highly detailed images of the lung to be produced. As the team reports in the Investigative Radiology, this method shows promise in detecting diseases such as pulmonary...

2014-05-18 16:20:49

Results from Boehringer Ingelheim, InterMune and IPFnet clinical trials discussed CHICAGO, May 18, 2014 /PRNewswire-USNewswire/ -- WHO: The Pulmonary Fibrosis Foundation (PFF) will discuss results from recent idiopathic pulmonary fibrosis (IPF) clinical trials in an upcoming webinar. Boehringer Ingelheim and InterMune both recently released data from their Phase III randomized, placebo-controlled trials, each demonstrating efficacy for those living with IPF. Also results from the...

2014-05-16 08:26:34

BRISBANE, Calif., May 16, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced it will provide compassionate use of pirfenidone through a multi-center Expanded Access Program (EAP) in the United States to be conducted under InterMune's U.S. IND. Pirfenidone is an investigational therapy in the U.S. and has not been approved by the U.S. Food and Drug Administration (FDA). Expanded access programs provide a mechanism for early access to an investigational drug in the...

2014-05-16 08:24:21

Now includes information about InterMune's Expanded Access Program CHICAGO, May 16, 2014 /PRNewswire/ -- The newly launched Pulmonary Fibrosis Foundation Patient Communication Center (PCC) has become the destination for the most up-to-date information for the pulmonary fibrosis community. The PCC now has information about the Expanded Access Program (EAP) for pirfenidone. "The Pulmonary Fibrosis Foundation (PFF) is committed to serve as an impartial resource for the PF community,"...

2014-05-12 08:31:50

-- Important New Data Reflecting Broad Pipeline in Fibrotic Diseases Will Be Presented -- BRISBANE, Calif., May 12, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that several investigational molecules and data from studies of pirfenidone will be presented at the 2014 International Conference of the American Thoracic Society (ATS), May 16 - 21, in San Diego, Calif. in a total of 18 abstracts. Updates on InterMune's small molecule fibrosis research programs,...

2014-04-28 10:15:29

Inflammation has long been considered an integral part of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis. New research at National Jewish Health, however, suggests that a little inflammation may also be crucial to the healing and repair processes in the lungs.  Elizabeth Redente, PhD, assistant professor of cell biology at National Jewish Health, and her colleagues report in the April 2014 issue of the American Journal of Respiratory Cell and Molecular...

2014-04-21 00:20:49

SAN DIEGO, April 21, 2014 /PRNewswire/ -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF). Our results indicate that very small inhaled doses deliver oral-superior, but short-lived lung levels. To understand if this increased lung dose may...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'